Corcept Therapeutics CORT Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

XER

Xeris Biopharma Holdings, Inc.XERS

$36.85M-4.5%

Crinetics PharmaceuticalsCRNX

$47.86M-5.8%

Cullinan Therapeutics, Inc.CGEM

$2.07M+36.3%

ImmunomeIMNM

$3.69M-22.6%

Praxis Precision Medicines, Inc.PRAX

$1.4M—

FAQ

What is Corcept Therapeutics's operating lease liabilities (total)?

Corcept Therapeutics (CORT) reported operating lease liabilities (total) of $9.42M in Q2 2026.

How has Corcept Therapeutics's operating lease liabilities (total) changed year-over-year?

Corcept Therapeutics's operating lease liabilities (total) increased by 42.6% year-over-year, from $6.61M to $9.42M.

What is the long-term trend for Corcept Therapeutics's operating lease liabilities (total)?

Over 5 years (2020 to 2025), Corcept Therapeutics's operating lease liabilities (total) has grown at a 19.1% compound annual growth rate (CAGR), from $2.55M to $6.11M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.